Inhaled Nitric Oxide Use and Outcomes in Critically Ill Children With a History of Prematurity. Author Aline Maddux, Peter Mourani, Russell Banks, Ron Reeder, Murray Pollack, Robert Berg, Kathleen Meert, Patrick McQuillen, Andrew Yates, Daniel Notterman, John Berger, Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network Publication Year 2021 Type Journal Article Abstract BACKGROUND: Inhaled nitric oxide (INO) is used to treat hypoxic respiratory failure without clear evidence of benefit. Future trials to evaluate its use will be designed based on an understanding of the populations in which this therapy is provided and with outcomes based on patient characteristics, for example, a history of premature birth.METHODS: This was a multi-center prospective observational study that evaluated subjects in the pediatric ICU who were treated with INO for a respiratory indication, excluding those treated in the neonatal ICU or treated for birth-related disease. We used logistic regression to evaluate characteristics associated with mortality and duration of mechanical ventilation. Specifically, we compared subjects born early preterm (<32 weeks post-conceptual age), late preterm (32-37 weeks post-conceptual age), and full term.RESULTS: A total of 163 children (median age [interquartile range], 1.8 [0.7-6.0] y) were included, 41 (25.2%) had a history of preterm birth (18 born early preterm and 23 born late preterm). INO was initiated for less-severe lung disease in the early preterm versus late preterm versus full-term subjects (median mean airway pressures, 16 vs 19 vs 19 cm HO; = .03), although the oxygenation index and oxygenation saturation index did not differ. The early preterm subjects had more ventilator-free days (median, 18.0, 7.0, 4.5 d; = .02) and lower 28-d mortality (0, 26.1, 32.0%; = .007). Lower respiratory tract disease, but not a history of prematurity, was independently associated with lower mortality.CONCLUSIONS: INO was used differently in early preterm subjects. Clinical trials that evaluate INO use should have standardized oxygenation deficit thresholds for initiation of therapy and should consider stratifying by early preterm status. Keywords Humans, Female, Child, Vasodilator Agents, Nitric Oxide, Pregnancy, Infant, Infant, Newborn, Respiratory Insufficiency, Administration, Inhalation, Critical Illness, Premature Birth Journal Respir Care Volume 66 Issue 10 Pages 1549-1559 Date Published 2021 Oct ISSN Number 1943-3654 DOI 10.4187/respcare.08766 Alternate Journal Respir Care PMCID PMC8810581 PMID 34552014 PubMedPubMed CentralGoogle ScholarBibTeXEndNote X3 XML